T1	Participants 213 280	4 consecutive prospective therapeutic trials including 236 patients
T2	Participants 576 587	71 patients
T3	Participants 925 945	patients without HBV
T4	Participants 972 998	patients with HBV markers.
T5	Participants 1002 1013	78 patients
T6	Participants 1124 1135	33 patients
T7	Participants 1470 1481	56 patients
